

# Koei Chin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1466840/publications.pdf>

Version: 2024-02-01

26  
papers

3,759  
citations

686830

13  
h-index

610482

24  
g-index

34  
all docs

34  
docs citations

34  
times ranked

7585  
citing authors

#	ARTICLE	IF	CITATIONS
1	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100525.	3.3	22
2	A framework for multiplex imaging optimization and reproducible analysis. <i>Communications Biology</i> , 2022, 5, 438.	2.0	17
3	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	20
4	Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. <i>Scientific Reports</i> , 2021, 11, 13630.	1.6	31
5	Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. <i>Breast Cancer Research</i> , 2021, 23, 81.	2.2	7
6	Toward reproducible, scalable, and robust data analysis across multiplex tissue imaging platforms. <i>Cell Reports Methods</i> , 2021, 1, 100053.	1.4	22
7	Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System. <i>Molecular Cancer Research</i> , 2021, 19, 623-635.	1.5	24
8	Multimomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. <i>Npj Precision Oncology</i> , 2021, 5, 92.	2.3	11
9	Oligonucleotide conjugated antibody strategies for cyclic immunostaining. <i>Scientific Reports</i> , 2021, 11, 23844.	1.6	11
10	Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis. <i>Methods in Molecular Biology</i> , 2020, 2055, 521-562.	0.4	33
11	RESTORE: Robust intEnSiTy nORMALization mETHOD for multiplexed imaging. <i>Communications Biology</i> , 2020, 3, 111.	2.0	28
12	Oligonucleotide conjugated antibodies permit highly multiplexed immunofluorescence for future use in clinical histopathology. <i>Journal of Biomedical Optics</i> , 2020, 25, 1.	1.4	16
13	Simultaneous Detection of RNAs and Proteins with Subcellular Resolution. <i>Methods in Molecular Biology</i> , 2020, 2161, 59-73.	0.4	1
14	Antibody Conjugated Oligonucleotides as a Platform for Cyclic Immunofluorescent Staining. <i>Microscopy and Microanalysis</i> , 2019, 25, 1206-1207.	0.2	1
15	Proteomics advances for precision therapy in ovarian cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 841-850.	1.3	5
16	GRB7 dependent proliferation of basal-like, HER2 positive human breast cancer cell lines is mediated in part by HER1 signaling. <i>Molecular Carcinogenesis</i> , 2019, 58, 699-707.	1.3	9
17	cmIF: A Python Library for Scalable Multiplex Imaging Pipelines. <i>Lecture Notes in Computer Science</i> , 2019, , 37-43.	1.0	3
18	Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. , 2019, 10881, .		1

#	ARTICLE	IF	CITATIONS
19	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. <i>Cell Systems</i> , 2018, 6, 329-342.e6.	2.9	72
20	Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. <i>Nature Communications</i> , 2018, 9, 3815.	5.8	137
21	Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution. <i>Scientific Reports</i> , 2017, 7, 16459.	1.6	6
22	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. <i>Cancer Cell</i> , 2014, 26, 863-879.	7.7	46
23	FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 381-390.	1.1	55
24	Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression. <i>Clinical Cancer Research</i> , 2009, 15, 3163-3171.	3.2	110
25	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. <i>Cancer Cell</i> , 2006, 10, 515-527.	7.7	2,729
26	In situ analyses of genome instability in breast cancer. <i>Nature Genetics</i> , 2004, 36, 984-988.	9.4	337